The weight loss drug, retatrutide was shown to provide more than double the weight loss of Ozempic’s highest dose
Eli Lilly’s experimental next-generation drug retatrutide achieved a greater therapeutic response of Novo Nordisk’s Ozempic on blood sugar control and produced greater than double the reduction in body weight in a study of adults with type 2 diabetes.
On Wednesday, the head-to-head trial compared 9mg and 12mg doses of Lilly’s retatrutide with a 2mg dose of Novo’s diabetes drug Ozempic, Lilly.
The result of the late-stage trial in both doses of retatrutide lowered A1C-a measure of blood sugar over time with an average of 2.2 compared with Ozempic 1.5% at 80 weeks. Notably, those taking retatrutide lost an average of 44.3 pounds on the 9mg dose and 47.4 pounds on 12mg, as compared with 20.9 pounds with Ozempic.
In this connection, Kenneth Custer, president of Lilly Cardiometabolic Health stated, “ Based on these results and those from across our Phase 3 program, we believe retatrutide, if approved, could shift the treatment paradigm for people living with type 2 diabetes, obesity and related cardiometabolic conditions.”
The once in a week drug retatrutide helps to activate three hormone receptors such as GLP-1, GIP, and glucagon. Nonetheless, triple-G weight loss drugs are expected to produce greater weight loss than earlier generations by combining reducing hunger, blood sugar control and increased calorie burning.